LLY vs ABBV
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LLY · Eli Lilly and Co$1,354.00 ▼ 0.79%
ABBV · AbbVie$291.31 ▲ 1.07%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LLY +41.0%
- ABBV +36.3%
Head to head
| Metric | LLY | ABBV |
|---|---|---|
| Price | $1,354.00 | $291.31 |
| Change today | ▼ 0.79% | ▲ 1.07% |
| Market cap | $1.27T | $514.92B |
| Return, 3 months | +10.1% | +17.5% |
| Return, year to date | +26.6% | +30.5% |
| Return, 1 year | +47.4% | +36.1% |
| P/E (TTM) | 43.9 | 50.1 |
| P/B | 31.6 | -112.3 |
| P/E percentile vs own 5y | 27th | 77th |
| Dividend yield | 0.49% | 2.34% |
| Revenue growth (YoY, latest qtr) | +38.6% | +10.3% |
| Net profit growth (YoY) | +15.5% | +2,144.7% |
| Gross margin | 83.6% | 73.7% |
| Operating margin | 51.3% | 36.0% |
| Net margin | 31.9% | 15.7% |
| Return on equity | 86.1% | – |
| Analyst target vs. price | +11.6% | +7.4% |
| Analyst buy share | 92% | 87% |
| RSI (14) | 61 | 60 |
| 30-day volatility | 34.3% | 23.8% |
| Max drawdown, 1 year | -23.2% | -15.7% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LLY is the largest of the group by market value.
- LLY has returned the most over the past year.
- LLY carries the lowest trailing P/E.
- ABBV pays the highest dividend yield.
- LLY is growing revenue fastest.
- LLY keeps the most profit per dollar of sales.
- ABBV has been the calmest stock over the last 30 days.